Company registration number 14791823 (England and Wales)
MEDGATE PRIME LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 APRIL 2024
PAGES FOR FILING WITH REGISTRAR
MEDGATE PRIME LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2
MEDGATE PRIME LTD
BALANCE SHEET
AS AT
30 APRIL 2024
30 April 2024
- 1 -
2024
Notes
£
£
Current assets
-
Creditors: amounts falling due within one year
3
(14,772)
Net current liabilities
(14,772)
Capital and reserves
Called up share capital
100
Profit and loss reserves
(14,872)
Total equity
(14,772)

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial Period ended 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the Period in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 7 October 2024
Mr KD Oduro
Director
Company registration number 14791823 (England and Wales)
MEDGATE PRIME LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 APRIL 2024
- 2 -
1
Accounting policies
Company information

MEDGATE PRIME LTD is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, Middlesex, HA5 5QA.

1.1
Reporting period

[ FRS 102 3.10 An entity shall present a complete set of financial statements (including comparative information as set out in paragraph 3.14) at least annually. When the end of an entity’s reporting period changes and the annual financial statements are presented for a period longer or shorter than one year, the entity shall disclose the following: (a) that fact; (b) the reason for using a longer or shorter period; and (c) the fact that comparative amounts presented in the financial statements (including the related notes) are not entirely comparable. ]

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

These financial statements for the Period ended 30 April 2024 are the first financial statements of MEDGATE PRIME LTD prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was . The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

2
Employees

The average monthly number of persons (including directors) employed by the company during the Period was:

2024
Number
Total
1
3
Creditors: amounts falling due within one year
2024
£
Other creditors
14,217
Accruals and deferred income
555
14,772
2024-04-302023-04-11false07 October 2024CCH SoftwareCCH Accounts Production 2024.100No description of principal activityMr KD Odurofalsefalse147918232023-04-112024-04-30147918232024-04-3014791823core:CurrentFinancialInstrumentscore:WithinOneYear2024-04-3014791823core:CurrentFinancialInstruments2024-04-3014791823core:ShareCapital2024-04-3014791823core:RetainedEarningsAccumulatedLosses2024-04-3014791823bus:Director12023-04-112024-04-3014791823bus:PrivateLimitedCompanyLtd2023-04-112024-04-3014791823bus:SmallCompaniesRegimeForAccounts2023-04-112024-04-3014791823bus:FRS1022023-04-112024-04-3014791823bus:AuditExemptWithAccountantsReport2023-04-112024-04-3014791823bus:FullAccounts2023-04-112024-04-30xbrli:purexbrli:sharesiso4217:GBP